REC-4881 in FAP: Data Update Webinar
Published December 8, 2025
Views 3.95K | Likes 77 | Comments 0
At a glance
Views
3,955
Likes
77
Comments
0
Performance vs. channel
Outlier score
Engagement rate
More features coming
We're working on new analytics and tools. Stay tuned.
About
On December 8, 2025, Recursion announced positive Phase 1b/2 data from the ongoing TUPELO trial of REC-4881, an investigational allosteric MEK1/2 inhibitor for familial adenomatous polyposis (FAP). In the Phase 2 portion of the study, REC-4881 demonstrated rapid and durable reductions in polyp burden, with 43% median …
- Published
- December 8, 2025
- Made for kids
- No
More features coming
We're working on new analytics and tools. Stay tuned.